<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631731</url>
  </required_header>
  <id_info>
    <org_study_id>2020/PID02542</org_study_id>
    <nct_id>NCT04631731</nct_id>
  </id_info>
  <brief_title>Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity</brief_title>
  <acronym>ICEMELT</acronym>
  <official_title>Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Sydney Local Health District</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Western Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western Sydney Local Health District</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and&#xD;
      skin Toxicity&quot; (ICEMELT) study is a prospective multicenter cohort study, enrolling patients&#xD;
      who are scheduled to receive (1) single agent PD1/L1 inhibitor; (2) PD1/L1 inhibitor plus&#xD;
      CTLA4 inhibitor; (3) platinum-based chemotherapy + PD1/L1 inhibitor; (4) PD1/L1 inhibitor and&#xD;
      tyrosine kinase inhibitor and (5) PD1/L1 inhibitor and vascular endothelial growth factor&#xD;
      (VEGF) inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is based on strong multidisciplinary collaboration between oncologists,&#xD;
      gastroenterologists/hepatologists, immunologists and basic scientists affiliated with (1)&#xD;
      Western Sydney University, (2) University of Sydney, (3) Western Sydney Local Health District&#xD;
      (4) New South Wales Health Pathology, (5) Westmead Institute for Medical Research.&#xD;
&#xD;
      Recruitment sites:&#xD;
&#xD;
        -  Blacktown Mt Druitt Hospital.&#xD;
&#xD;
        -  Westmead Hospital.&#xD;
&#xD;
      Research samples collection, processing and storage:&#xD;
&#xD;
        -  Blacktown Clinical School, Western Sydney University.&#xD;
&#xD;
        -  Westmead Institute for Medical Research, the University of Sydney.&#xD;
&#xD;
        -  New South Wales Health Pathology.&#xD;
&#xD;
      Potential patients will be identified by study investigators at Oncology clinics. After&#xD;
      informed consent, clinicopathological data including patients' demographics, past medical&#xD;
      history, cancer staging, relevant anticancer treatment, response/progression and survival&#xD;
      will be collected longitudinally.&#xD;
&#xD;
      The following specimens will be collected from all participating patients at baseline&#xD;
      (pre-treatment stage):&#xD;
&#xD;
        -  Peripheral blood (3 x 10mL EDTA tubes)&#xD;
&#xD;
        -  FibroScan (CAP score for elucidating pre-existing liver fibrosis)&#xD;
&#xD;
        -  Formalin-Fixed Paraffin-Embedded (FFPE) samples (one block) from core biopsies which is&#xD;
           a part of routine care for cancer patients.&#xD;
&#xD;
      The following specimens will be collected after IPI + NIVO therapeutic regimen will be&#xD;
      commenced (week 6-9 after ICI-therapy commencement):&#xD;
&#xD;
      • Peripheral blood (3 x 10mL EDTA tubes)&#xD;
&#xD;
      Upon development of potential grade ≥2 irAEs, the following samples will be collected:&#xD;
&#xD;
        -  Peripheral blood (3 x 10mL EDTA tubes)&#xD;
&#xD;
        -  FibroScan (for patients with hepatic irAEs)&#xD;
&#xD;
        -  Tissue samples (if biopsies are collected as per standard of care for patients with&#xD;
           immune-mediated colitis who will be required to undergo colonoscopy)&#xD;
&#xD;
      Peripheral blood samples from patients will be collected using 10ml EDTA vacutainer tubes&#xD;
      (x3) and processed within 12 hours of collection by research staff at each site. Plasma will&#xD;
      be used for miRNA assay. PBMCs will be split into 5 cryotubes and used for flow cytometry&#xD;
      phenotyping of T cells (1 tube) and RNA/DNA profiling (2 tubes).&#xD;
&#xD;
      Consent to the study will allow researchers to access the baseline archive diagnostic FFPE&#xD;
      tissue samples. With implementing cutting-edge spatial analysis tool we aim to define tissue&#xD;
      heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and&#xD;
      correlate it with the expression of specific coding/non-coding RNAs in ICI-treated cancer&#xD;
      patients.&#xD;
&#xD;
      Fresh tissue samples obtained from patients with severe immune-mediated colitis during the&#xD;
      colonoscopy or liver biopsy will be processed to obtain total RNA and immune cells for RNA&#xD;
      sequencing and mass spectrometry (CyTOF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">November 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify RNA-based risk factors associated with immune-related adverse events</measure>
    <time_frame>Week 0-48</time_frame>
    <description>Identify changes in RNAs following the initiation of ICI therapy.&#xD;
Identify specific RNAs whose expression is significantly altered in patients with immune-related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish mechanisms responsible for RNA-irAE association and to pinpoint potential therapeutic targets</measure>
    <time_frame>Week 0-48</time_frame>
    <description>Identification of mRNAs regulated by clinically relevant ncRNAs.&#xD;
The signaling pathway(s) regulated by clinically relevant ncRNAs in patients with immune-related adverse events.&#xD;
Identification of modifiable targets within pathway(s) driving immune-related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify immune signatures of CD4+/CD8+ T cells in patients with immune-related adverse events.</measure>
    <time_frame>Week 0-48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish clinical risk factors significantly correlated with the onset of irAEs</measure>
    <time_frame>Week 0-48</time_frame>
    <description>• The goal is to generate a list of clinical parameters statistically correlated with irAEs.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Single agent PD-1/L1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1/L1 inhibitor + CTLA-4 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Platinum-based chemotherapy + PD-1/L1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1/L1 inhibitor + tyrosine kinase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1/L1 inhibitor + VEGF inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood screening</intervention_name>
    <description>Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.</description>
    <arm_group_label>PD-1/L1 inhibitor + CTLA-4 inhibitor</arm_group_label>
    <arm_group_label>PD-1/L1 inhibitor + VEGF inhibitor</arm_group_label>
    <arm_group_label>PD-1/L1 inhibitor + tyrosine kinase inhibitor</arm_group_label>
    <arm_group_label>Platinum-based chemotherapy + PD-1/L1 inhibitor</arm_group_label>
    <arm_group_label>Single agent PD-1/L1 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tissue screening</intervention_name>
    <description>Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.</description>
    <arm_group_label>PD-1/L1 inhibitor + CTLA-4 inhibitor</arm_group_label>
    <arm_group_label>PD-1/L1 inhibitor + VEGF inhibitor</arm_group_label>
    <arm_group_label>PD-1/L1 inhibitor + tyrosine kinase inhibitor</arm_group_label>
    <arm_group_label>Platinum-based chemotherapy + PD-1/L1 inhibitor</arm_group_label>
    <arm_group_label>Single agent PD-1/L1 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to comprehend the requirements and procedures for the study and to provide&#xD;
             informed consent before entering the study&#xD;
&#xD;
          -  Solid malignant tumour (stage III-IV)&#xD;
&#xD;
          -  Treated with ICI-based therapeutic regimens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give written informed consent&#xD;
&#xD;
          -  Patients with a cognitive impairment, an intellectual disability or a mental condition&#xD;
             that will interfere with the patient's ability to understand the requirements of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Golo Ahlenstiel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Sydney Local Health District</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitrii Shek, Dr</last_name>
    <phone>+61 412 035 533</phone>
    <email>Dmitri.Shek@health.nsw.gov.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Gao, Dr</last_name>
      <email>Bo.Gao@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Adnan Nagrial, A/Professor</last_name>
      <email>Adnan.Nagrial@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Blacktown Mt Druitt Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Golo Ahlenstiel, Professor</last_name>
      <email>Golo.Ahlenstiel@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Bo Gao, Dr</last_name>
      <email>Bo.Gao@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Shek D, Read SA, Akhuba L, Qiao L, Gao B, Nagrial A, Carlino MS, Ahlenstiel G. Non-coding RNA and immune-checkpoint inhibitors: friends or foes? Immunotherapy. 2020 May;12(7):513-529. doi: 10.2217/imt-2019-0204. Epub 2020 May 7. Review.</citation>
    <PMID>32378480</PMID>
  </reference>
  <reference>
    <citation>Shek D, Read SA, Nagrial A, Carlino MS, Gao B, George J, Ahlenstiel G. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist. 2021 Jul;26(7):e1216-e1225. doi: 10.1002/onco.13776. Epub 2021 Apr 21. Review.</citation>
    <PMID>33818870</PMID>
  </reference>
  <reference>
    <citation>Shek D, Akhuba L, Carlino MS, Nagrial A, Moujaber T, Read SA, Gao B, Ahlenstiel G. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. Cancers (Basel). 2021 Aug 27;13(17). pii: 4345. doi: 10.3390/cancers13174345. Review.</citation>
    <PMID>34503155</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Sydney Local Health District</investigator_affiliation>
    <investigator_full_name>Golo Ahlenstiel</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Immune-checkpoint inhibitors</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Iplimumab</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Tislelizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

